| Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. Co.'s products are sold worldwide, primarily to wholesalers, specialty distributors, retail pharmacies, hospitals, government entities and the medical profession. Co. manufactures products in the United States and Puerto Rico and has manufacturing operations in two foreign countries. Co. has products in the following therapeutic classes: hematology, oncology, cardiovascular and immunology. Co.'s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. |
When researching a stock like Celgene, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from CELG Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for CELG stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of those ways is to calculate a Simpe Moving Average ("SMA") by looking back a certain number of days. One of the most popular "longer look-backs" is the CELG 200 day moving average ("CELG 200 DMA"), while one of the most popular "shorter look-backs" is the CELG 50 day moving average ("CELG 50 DMA"). A chart showing both of these popular moving averages is shown on this page for Celgene.